These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3724664)

  • 1. Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development.
    Jahrling PB; Peters CJ
    Med Microbiol Immunol; 1986; 175(2-3):165-7. PubMed ID: 3724664
    [No Abstract]   [Full Text] [Related]  

  • 2. Serological and biological evidence that Lassa-complex arenaviruses are widely distributed in Africa.
    Kiley MP; Swanepoel R; Mitchell SW; Lange JV; Gonzalez JP; McCormick JB
    Med Microbiol Immunol; 1986; 175(2-3):161-3. PubMed ID: 3724663
    [No Abstract]   [Full Text] [Related]  

  • 3. Evolutionary biology of a Lassa virus complex.
    Gonzalez JP; Georges AJ; Kiley MP; Meunier DM; Peters CJ; McCormick JB
    Med Microbiol Immunol; 1986; 175(2-3):157-9. PubMed ID: 3724662
    [No Abstract]   [Full Text] [Related]  

  • 4. Lassa fever virus in Senegal.
    Saluzzo JF; Adam F; McCormick JB; Digoutte JP
    J Infect Dis; 1988 Mar; 157(3):605. PubMed ID: 3343533
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibodies to Lassa and Lassa-like viruses in man and mammals in the Central African Republic.
    Georges AJ; Gonzalez JP; Abdul-Wahid S; Saluzzo JF; Meunier DM; McCormick JB
    Trans R Soc Trop Med Hyg; 1985; 79(1):78-9. PubMed ID: 2986324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates.
    Jahrling PB; Frame JD; Smith SB; Monson MH
    Trans R Soc Trop Med Hyg; 1985; 79(3):374-9. PubMed ID: 3898483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.
    Clegg JC; Lloyd G
    Lancet; 1987 Jul; 2(8552):186-8. PubMed ID: 2885642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
    Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
    Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
    Carrion R; Patterson JL; Johnson C; Gonzales M; Moreira CR; Ticer A; Brasky K; Hubbard GB; Moshkoff D; Zapata J; Salvato MS; Lukashevich IS
    Vaccine; 2007 May; 25(20):4093-102. PubMed ID: 17360080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible approaches to a vaccine against Lassa fever.
    Clegg JC
    Trans R Soc Trop Med Hyg; 1984; 78(3):307-10. PubMed ID: 6464128
    [No Abstract]   [Full Text] [Related]  

  • 11. Towards a human Lassa fever vaccine.
    Fisher-Hoch SP; McCormick JB
    Rev Med Virol; 2001; 11(5):331-41. PubMed ID: 11590670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics of the immune response in mice immunized with the inactivated Lassa virus].
    Ignat'ev GM; Golubev VP; Godneva AT; Petkevich AS; Torop AV
    Vopr Virusol; 1989; 34(2):213-6. PubMed ID: 2474905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, epidemiologic, and therapeutic aspects of Lassa fever.
    McCormick JB
    Med Microbiol Immunol; 1986; 175(2-3):153-5. PubMed ID: 3724661
    [No Abstract]   [Full Text] [Related]  

  • 14. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
    Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever].
    Firsova IV; Shatokhina IV; Borisevich IV; Evseev AA; Maksimov VA; Pantiukhov VB; Khmelev AL
    Vopr Virusol; 2003; 48(6):43-5. PubMed ID: 14708232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lassa fever (arenaviruses) as a public health problem.
    Fabiyi A
    Bull Pan Am Health Organ; 1976; 10(4):335-7. PubMed ID: 1026322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A trial to produce an inactivated Lassa fever vaccine].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Vopr Virusol; 1993; 38(6):276-9. PubMed ID: 8303891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization.
    Jahrling PB; Frame JD; Rhoderick JB; Monson MH
    Trans R Soc Trop Med Hyg; 1985; 79(3):380-4. PubMed ID: 3898484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dynamics of antigen and antibody accumulation in adult mice, infected with Lassa virus].
    Vladyko AS; Surikova LE; Kramarenko LP; Bystrova SI; Torop AV
    Vopr Virusol; 1989; 34(1):100-3. PubMed ID: 2658319
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.